BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 4, 2003
View Archived Issues
Actelion, Celltech Receive FDA Approval For Zavesca
Actelion Ltd. and partner Celltech Group plc received FDA clearance to market Zavesca to Type I Gaucher's disease patients who are not candidates for Cerezyme, an orphan product made by Genzyme Corp.(BioWorld Today)
Read More
Esperion's Public Offering Raises $64M For Pipeline
Read More
Viruses, Bacteria Differ, Yet Share Innate Immune System's Strategy To Identify Lethal Sepsis Infection
Read More
Biopure: FDA Asks For More Hemopure Data, No New Trials
Read More
Other News To Note
Read More
Appointments And Advancements
Read More